Disc Medicine, Inc. (IRON) Form 424B5 — Oct 19, 2026
Disc Medicine filed a 424B5 prospectus supplement for a $350 million underwritten offering of common stock and pre-funded warrants, priced one day after announcing positive topline results from the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), which met all primary and secondary endpoints. Jefferies, Leerink, Morgan Stanley, and Cantor are joint book-running managers, with a 30-day option to purchase up to an additional $52.5 million of shares. IRON's closing price on October 19, 2026 was $78.93, and the offering follows an earlier CRL on the bitopertin NDA that the APOLLO data are intended to overcome.
Key figures
- Cash Position
- 682800000
- Gross Proceeds
- 350000000
- Offering Price
- 0
- Shares Outstanding
- 38345666
- Greenshoe amount
- $52,500,000 additional shares (30-day underwriter option)
- Remaining atm capacity
- $189.9 million
- Prior close oct 19 2026
- $78.93
- Cash runway with offering
- into 2030
- Cash runway without offering
- into 2029
- Net tangible book value per share
- $16.80
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.